Key facts
- GT Metabolic’s last known valuation is $56.0M (Jan 2023).
- It has raised $46.5M; the latest was Later Stage VC ($27.9M) in Dec 2025.
- Notable investors include HealthTech Capital, Krillion Ventures, AB Medica, Ceros Financial Services.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for GT Metabolic
- ·The full record, as it builds
Funding rounds
No funding rounds for GT Metabolic are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About GT Metabolic
Developer of a gastrointestinal device system designed to perform a minimally invasive procedure in the field of gastroenterology. The company's system can be used for medical procedures by creating a magnetic connection in the gastrointestinal tract, enabling medical professionals with a potentially less invasive approach compared to traditional surgical methods.
- Sector
- Healthcare
- HQ
- San Jose, CA, United States
- Founded
- 2020
- Employees
- 19
- Website
- gtmetabolic.com/
- Ownership
- Privately Held (backing)
GT Metabolic doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in GT Metabolic shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on GT Metabolic in its N-PORT filings yet. We sweep new filings monthly.